Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions

• Status: Unknown status
• Trial end date: 2019-05-13
• Target enrollment: 0
• Participant gender: All

Summary

A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.
• Treatments: Sarpogrelate

Criteria

Inclusion Criteria:

• Healthy, non-smoking, male and female subjects, 19 years of age or older

• BMI ≥ 18.0 and ≤ 30.0 kg/m2.

• Females who participate in this study will be of childbearing or non- childbearing potential

Exclusion Criteria:

• Know history or presence of clinically significant neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, genitourinary, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the investigator, would jeopardized the safety of the subject or impact the validity of the study results